Clinical trials: B Cell Leukemia, open to volunteers
Non-hodgkin Lymphoma,B Cell, Multiple Myeloma
CAR T-cell Therapy in Patients With Renal Dysfunction
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
- Conditions
- Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
- Trial name
- NCT05909059
- Testing
- Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received…
- Trial name
- NCT06136559
- Testing
- Nemtabrutinib, Ibrutinib, Acalabrutinib
- Where
- 206 sites in United States, Australia and 27 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Ibrutinib, an inhibitor of Bruton´s tyrosine kinase (BTK) is approved in CLL as continuous, daily administration of 420 mg orally until progression.
- Trial name
- IbruOnOff (NCT04771507)
- Testing
- Ibrutinib
- Where
- 9 sites in Norway, Sweden
- Volunteers
- 50 people
- Sponsor
- Jeanette Lundin
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia.
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT04502394
- Testing
- KRT-232, acalabrutinib
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- Kartos Therapeutics, Inc.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
- Trial name
- NCT06927466
- Testing
- B019
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back…
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Trial name
- NCT04169737
- Testing
- Acalabrutinib, Obinutuzumab, Venetoclax
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Cancer, Colon Cancer
Precision Physical Exercise for Personalized Onco-Hematology.
Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients.
- Conditions
- Hematologic Cancer, Colon Cancer, Breast Cancer, Lymphoma
- Trial name
- PEPOH (NCT07286539)
- Testing
- Supervised Intervention, Home-based Intervention
- Volunteers
- 150 people
- Sponsor
- University of Salamanca
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.
- Conditions
- Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult, B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05648019
- Testing
- Anti-CD19 CAR T-cells
- Where
- 2 sites in Singapore
- Volunteers
- 40 people
- Sponsor
- KK Women's and Children's Hospital
Relapsed/Refractory Pediatric B-ALL
JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL
This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of…
- Trial name
- NCT07406178
- Testing
- JY509 universal NK cell injection
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Lymphocytic Leukemia
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
- Trial name
- ALICIA(BY) (NCT07288515)
- Where
- 4 sites in Belarus
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Acute Lymphocytic Leukemia (ALL)
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy.
- Trial name
- NCT07053059
- Testing
- Obecabtagene autoleucel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and <18 years)…
- Trial name
- NCT05748171
- Testing
- Inotuzumab ozogamicin, ALLR3
- Where
- 65 sites in Austria, Belgium and 13 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
B Cell Malignancies
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
This is a phase I/II trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies.
- Trial name
- NCT07135466
- Testing
- CD22 CAR-T cells
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Relapsed or Refractory B Cell Leukemia and Lymphoma
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
- Trial name
- NCT06834529
- Testing
- CAR2219-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
- Trial name
- NCT06581081
- Testing
- Senl_B19 autologous CAR-T (S1904) treatment
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT05334823
- Testing
- pCAR-19B cells
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
- Trial name
- NCT06395103
- Testing
- Zilovertamab vedotin
- Where
- 71 sites in United States, Australia and 21 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial
This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 32 adult patients with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL).
- Trial name
- Ph- ALL-2026 (NCT07643103)
- Testing
- Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Mantle Cell Lymphoma, Follicular Lymphoma
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells…
- Conditions
- Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT04223765
- Testing
- CAR.k.28, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
- Conditions
- B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05281809
- Testing
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- John Lister